



(51) International Patent Classification:

C07K 14/00 (2006.01) **A61K 38/16** (2006.01)
C07K 14/545 (2006.01) **A61K 38/20** (2006.01)
C07K 19/00 (2006.01) **A61P 19/02** (2006.01)
C12N 15/09 (2006.01) **A61P 9/06** (2006.01)
C12N 15/117 (2010.01) **A61P 3/10** (2006.01)
C12N 15/66 (2006.01)

(21) International Application Number:

PCT/US2013/026349

(22) International Filing Date:

15 February 2013 (15.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US): **R-PHARM, CJSC (CLOSED JOINT STOCK COMPANY)** [—/RU]; 19, 1 bld., Berzarina Street, 123154 Moscow (RU).

(72) Inventors; and

(71) Applicants (for US only): **LAVROVSKY, Yan** [US/US]; 10158 Wateridge Circle, #136, San Diego, CA 92121 (US). **XU, Ting** [CN/US]; 11 Dawson Drive, Sudbury, MA 01776 (US). **REPIK, Alexey** [RU/RU]; 3 Osemmiy Boulevard, Apt. 106, Moscow, 121609 (RU). **XU, Tao** [CN/CN]; Suit 41, Bld. 67, Songze JiaYuan, Suzhou, Jiangsu Province, 215125 (CN). **IGNATIEV, Vasily** [RU/RU]; 13 Skolkovskoye Shosse, Apt. 212, Moscow,

121353 (RU). **SAMSONOV, Mikhail** [RU/RU]; 74-6-77 Leningradsky Prospect, Moscow, 125313 (RU).

(74) Agent: **KORKHIN, Yakov, M.**; SciTech Legal PC, PO Box 15696, Boston, MA 02215 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))


(54) Title: IL-1 β INHIBITOR COMPOSITION AND USE THEREOF

FIGURE 1

(57) Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1 β . In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1 β and attenuating its function. The heterodimeric protein assembly comprises an extracellular portions of human IL-1R1 and of human IL-1RAcP, or their functional fragments. Each, the IL-1R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. DNA expression vectors and expression systems for overproducing the polypeptides in mammalian cells are also provided for.